Table 2 Distribution of the antihypertensive therapy and of the classes of BP-lowering drugs among the patients divided according to the level of renal function

From: Clinical correlates of renal dysfunction in hypertensive patients without cardiovascular complications: the REDHY study

 

No CKD (n=1329)

CKD 1 (n=164)

CKD 2 (n=178)

CKD 3 (n=139)

CKD 4 (n=42)

CKD 5 (n=4)

χ2-test (P)

Subjects pharmacologically treated for hypertension (%)

67.8

77*

80*

71

68.8

50

0.001

ACE inhibitors (%)

23.9

26.9

28.8

23

23.7

0

NS

AT1 blockers (%)

16.9

19.6

20.9

18

14.1

25

NS

β- and α-β-Blockers (%)

7.5

10.4

9

7.8

0

0

NS

Calcium antagonists (%)

8.2

7.3

9.5

8.5

16.7

0

NS

α-Blockers (%)

2

2.4

2.2

2.2

2.4

0

NS

Combination of two or more drugs (%)

9.3

10.4

9.6

11.5

11.9

25

NS

  1. Abbreviations: CKD, chronic kidney disease; NS, not significant.
  2. *Significantly different from the ‘No CKD’ group.
Back to article page